Perrigo offloads Elan Alzheimer drug candidate

Company does deal with partner Transition Therapeutics as it separately spends $51m on over-the-counter products in Australia

Perrigo  president and chief executive Joe Papa. Photograph: Brenda Fitzsimons

Perrigo president and chief executive Joe Papa. Photograph: Brenda Fitzsimons

 

In a statement, Perrigo said it had done a deal with Canadian group Transition Therapeutics, the partner in the ELND005 programme, to progress its clinical development as a therapy for Alzheimer’s disease, bipolar disorder and Down syndrome.

Under the transaction, Transition Therapeutics will acquire all of the shares of the Irish Perrigo subsidiary responsible for developing ELND005. Perrigo will also pay $15 million for which it will receive 2,255,640 shares in Transition as well as milestone payments if the drug is eventually commercialised.

Separately yesterday, Perrigo announced it had acquired a portfolio of over-the-counter products in Australia and New Zealand. The $51 million cash deal will see Perrigo take over a range of analgesics, vitamins and supplements from a company called Aspen, which currently sells primarily through supermarkets.

The US company, which moved its headquarters to Ireland as part of the Elan deal, said the acquisitions were expected to generate sales of at least $20 million this year.